The number of EBV-positive child patients with HL varies in different countries and regions. In developing countries the number of child patients with this disease is higher than in the patient population of economically advanced countries. The authors examined 24 patients under 10 years with Hodgkin's lymphoma. Twenty patients were males, four females. In ten cases according to histological examination type II of HL was involved--nodular sclerosis (7 boys, 3 girls). In 14 instances the authors detected the mixed cellularity type (13 boys and 1 girl). EBV positivity was assessed immunohistologically by means of the antibody against LMP-1 and EBER-1 by the method of in situ hybridization. In 20 EBV positive HL 18 boys and 2 girls were affected. EBV positivity was proved in 83%. The marked intersexual difference in different EBV positive HL has not been explained unequivocally so far. The authors proved, that 14 EBV positive HL were type III--mixed cellularity. In 6 cases the type of nodular sclerosis was involved. The authors assume that marked positivity of child patients is associated with the initial massive EBV infection. EBV positive tumour cells are to a considerable extent removed by the immune apparatus and thus in the second and third decade EBV negative patients predominate.

Download full-text PDF

Source

Publication Analysis

Top Keywords

ebv positive
16
child patients
12
hodgkin's lymphoma
8
boys girls
8
ebv
8
ebv positivity
8
patients
6
[ebv-positive hodgkin's
4
lymphoma children
4
children years]
4

Similar Publications

Background: The prospective application of plasma Epstein-Barr virus (EBV) DNA load as a noninvasive measure of intestinal EBV infection remains unexplored. This study aims to identify ideal threshold levels for plasma EBV DNA loads in the diagnosis and outcome prediction of intestinal EBV infection, particularly in cases of primary intestinal lymphoproliferative diseases and inflammatory bowel disease (IBD).

Methods: Receiver operating characteristic (ROC) curves were examined to determine suitable thresholds for plasma EBV DNA load in diagnosing intestinal EBV infection and predicting its prognosis.

View Article and Find Full Text PDF

Objective: The objective of this study is to evaluate and compare the clinical utility of 18F-fluoro-2-deoxy-d-glucose PET and computed tomography (18F-FDG PET/CT) in detecting recurrence and metastasis in patients with nasopharyngeal carcinoma (NPC) who exhibit elevated levels of Epstein-Barr virus (EBV) DNA following treatment.

Methods: A total of 103 patients with NPC were studied retrospectively. All patients were in remission following initial treatment.

View Article and Find Full Text PDF

Splenic infarction with infectious mononucleosis (IM) caused by Epstein-Barr Virus (EBV) has been reported as a rare complication of IM. The monospot test, often used to diagnose EBV-related IM, may produce false-negative results, especially in atypical presentations or early stages of infection. This report describes the case of a monospot-negative patient who developed splenic infarction as a complication of IM.

View Article and Find Full Text PDF

Kikuchi-Fujimoto disease: 6 years old boy rare case in Syria.

Oxf Med Case Reports

January 2025

Department of Pediatrics at Al-Baath Hospital, Al-Baath University, Al-Wehda, Homs, Syria.

Kikuchi-Fujimoto disease (KFD) is a rare condition first identified in Japan in 1972. It typically presents with high fever and lymph node swelling, and may be linked to autoimmune conditions or viral infections. A 6-year-old boy presented with cervical enlargement and recurrent high fever.

View Article and Find Full Text PDF

Purpose: A first-in-human phase one study was conducted in nasopharyngeal carcinoma (NPC) patients to assess the safety and tolerability of VK-2019, a small molecule selective inhibitor of Epstein-Barr virus Nuclear Antigen 1 (EBNA1).

Patients And Methods: Pharmacokinetic and pharmacodynamic studies, including circulating tumor EBV DNA plasma levels, were performed. Twenty-three patients received VK-2019 orally once daily at doses ranging from 60 to 1800 mg using an accelerated titration design, with cohort expansion at 1800 mg.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!